ПОДДЕРЖИВАЮЩАЯ ТЕРАПИЯ РЕМИССИИ У ПАЦИЕНТОВ С МНОЖЕСТВЕННОЙ МИЕЛОМОЙ
Igor Iskrov, А.Л. Усс, V. V. Smolnikova et al. · Проблемы здоровья и экологии · 2011
High-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) can achieve remission in 90 % patients with multiple myeloma. Unfortunately, the duration of this remission is less than 3 years. The development of the methods to maintain the remission and to control minimal residual disease in patients with multiple myeloma is a pressing task for hematologists. In the group of the patients treated with α-interferon, after HDC with autologous HSCT the dual response rate was significantly higher (p < 0,05) and relapse rates were significantly lower (p < 0,05) in comparison with the group of patients treated that α-interferon.
Cited by 0 works.